Thiazolidinediones (TZDs), which act through the nuclear receptor peroxisome proliferator activated receptor-γ (PPARγ), are a widely prescribed class of drugs for type 2 diabetes; however, their use has been challenged by a number of side effects. Here the authors outline recent advances in our understanding of the modulation of the PPARγ pathway in metabolism and discuss how these insights might be used to explain the adverse side effects of TZD therapy and develop a new generation of safer PPARγ-targeting drugs.
- Maryam Ahmadian
- Jae Myoung Suh
- Ronald M Evans